KBP Biosciences Announces Data Presentation at the American Society of Nephrology Annual Meeting


PRINCETON, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- KBP Biosciences Holdings Limited (KBP Biosciences), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative therapeutics for the treatment of major diseases with large underserved patient populations, today announced upcoming data to be presented at the American Society of Nephrology (ASN) Annual Meeting, being held in a virtual format from October 22-25, 2020. Frederic Jaisser, Head of the Physiology Department, Cordeliers Research Center, Research Director, INSERM, is presenting an abstract entitled: “The non-steroidal mineralocorticoid receptor antagonist KBP-5074 limits albuminuria with improved efficacy and safety compared to eplerenone.”

See the original post here:
KBP Biosciences Announces Data Presentation at the American Society of Nephrology Annual Meeting

Related Posts